Systemic lupus erythematosus (SLE) is an autoantibody-mediated systemic autoimmune disease, predominantly affecting young females in there childbearing ages. lupus pregnancy is labeled as 'high-risk' pregnancy. Disease flare of SLE can occur during pregnancy. Pregnancy related complications are common with SLE. Fetal outcome is also poor. There is a increased risk of spontaneous miscarriage, intra-uterine growth restriction, fetal death, neonatal lupus syndrome, preeclampsia and pre-term delivery. Over the years, the pregnancy outcomes have significantly improved. In recent years the rate of pregnancy loss has decreased from 43% to 17%. 1 SLE is not itself a contra-indication to pregnancy, with the exception of organ-system complications such as pulmonary hypertension and renal failure, advanced heart failure, previous severe preeclampsia or HELLP syndrome despite treatment. Active disease and lupus nephritis increase the risk of fetal loss and other adverse outcomes 2 . Proteinuria, hypertension, thrombocytopenia, and presence of anti-phospholipid antibodies are other negative predictors for fetal survival 3 . Fertility is normal as autoimmune ovarian failure is rare. menstrual disorders or ovarian failure may occur in end-stage renal disease, drugs used to treat SLE (e.g. cyclophosphamide).
Flares may occur during all three trimesters with equal frequency, and often in the immediate postpartum period. It is not possible to predict when, or if, an individual patient will flare. Flare is more likely if disease has been active within 6 months of conception. The main predictor of a flare during pregnancy and its degree is the number and the severity of flares before conception. Prophylactic steroids does not lower the frequency of flares. The fatal complications of SLE flare are renal involvement and CNS manifestation.
Many physiological changes of pregnancy may overlap with features of active disease, making differentiation difficult. Some common laboratory tests also become less reliable: mild anemia and thrombocytopenia are common, erythrocyte sedimentation rate is raised, and up to 300mg/day proteinuria can occur during normal pregnancy. Complement levels rise by 10-50% during normal pregnancy and may appear to remain in the 'normal' range, despite disease activity. Thus, the trend of complement levels becomes more important than absolute values. Low sand declining levels of complement during pregnancy found to be associated with poor pregnancy outcomes 4 . Anti-dsDNA antibodies may be helpful in evaluation of disease activity 4 .
Active SLE at the time of conception is the strongest predictor of adverse pregnancy outcomes 5 . So, in women with SLE pregnancies should be planned during periods of disease control. Prior to conception a management strategy should be agreed in full consultation with the patient. Thyroid function should be assessed as 1 hypothyroidism in SLE is associated with poorer outcomes 6 . They should be counseled about the risk of disease flares, higher rates of pregnancy complications, poor obstetric outcomes, the risk of neonatal lupus syndromes and the need for optimal disease control with safe medications during pregnancy.
Patient should be evaluated in a comprehensive and up-to-date manner for 1. Major organ function-If severe dysfunction is present, pregnancy is not advised. Special emphasis is given on the kidneys and thrombocytopenia.
2. Assessment of disease activity -if active disease pregnancy is deferred, if stableadvised for pregnancy.
3. Autoantibody profile-for risk evaluation aPL & anti Ro antibody to be done.
4. Review medication and adjust to achieve optimal control on safe drugs before conception.
Women with SLE should be followed up by an obstetrician knowledgeable in high-risk pregnancies. Frequency of clinic visits depends upon need, but the recommendation is a minimum of monthly visits until 28 weeks, fortnightly visits to 36 weeks and then weekly visits. Baseline tests should include: complement studies (C3, C4, CH5O), antidsDNA , anticardiolipin antibodies, lupus anticoagulant (Russell viper venom time), anti-SSA and SSB (Ro and La), microscopic urinalysis, a 24-hour urine collection to determine total protein, total calcium, creatinine clearance, and protein-tocreatinine ratio. Before conception or in early pregnancy antihypertensive medications should be switched to those that are safe in pregnancy (methyldopa, labetalol and nifedipine). Angiotensin-converting-enzyme inhibitors and Angiotensin-2-receptor antagonists are associated with renal dysfunction in the fetus and therefore should be avoided. Diuretics decrease intravascular volume, hence should be avoided.If loop diuretics are needed to maintain renal function, they should be continued. Frusemide is the loop diuretic with the best track record for treatment of chronic renal failure in pregnancy. It poses a low risk to the fetus.
If antiphospholipid syndrome is present, there is greatly increased risk of thrombosis and foetal loss.Heparin does not cross the placenta and is the anticoagulant of choice during pregnancy. Warfarin should be avoided during pregnancy, especially during the first trimester, due to the risk of warfarin embryopathy syndrome.Calcium supplementation should be given routinely to all pregnant women with SLE, especially those receiving corticosteroids and heparin. Insufficient vitamin D levels during pregnancy are associated with higher pregnancy morbidity including gestational diabetes, pre-eclampsia, and small for gestational age infants. 8 Bisphosphonates should be discontinued 6-12 months prior to pregnancy. After delivery heart rate of the baby should be counted and also there should be a search for any cutaneous lesion.
Treatment of established congenital heart block (CHB) is difficult23. Therefore, it is better to prevent during pregnancy. For cutaneous lesion with topical steroids can be applied. Most of drugs are excreted in breast milk in variable amounts. maternal intake of less than or up to 30 mg/day of prednisolone, warfarin, cyclosporine in standard doses and weekly chloroquine for malaria prophylaxis are considered safe for breastfed babies. If the dose of prednisolone is greater than 30 mg/day, feeding should be avoided for 4 hours after ingestion of the morning dose of steroid. By this time the blood levels are low and very limited amounts are secreted into the milk. If mother is on cyclophosphamide, azathioprine, hydroxychloroquine for SLE breastfeeding is contraindicated.
During the postpartum period, the mother should be carefully followed up for any sign of infection and disease exacerbation; both require aggressive treatment. In Antiphospholipid antibody Syndrome, warfarin is restarted after bleeding stops. Barrier methods are the safest method for contraception. However, low dose estrogen or progesterone only pills are relatively safe. High dose estrogen containing pill should be avoided. OCP should be avoided in antiphospholipid syndrome, other thromboembolic diseases, highly active disease, migraine, Raynaud's phenomenon. Intrauterine devices use causes infections like endometritis, PID etc. SLE is a multisystem disease. So a multidiscciplinary approach, with close medical, obstetric and neonatal monitoring, is essential for optimal outcomes.
